drugset / Trial / NCT05994157
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA) to establish optimal and safe therapeutic doses and dosing schedule of CD38-SADA, and 177Lu-DOTA.
Timeline
- Start
- 2025-04-21
- Primary completion
- 2025-10-15
- Completion
- 2025-10-15
Outcome
Outcome not reported
Stopped (Enrollment): “Study is terminated by Sponsor decision due to recruitment challenges.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTA | Unknown | — | Intravenous |
| Subject | CD38-SADA | Unknown | — | Intravenous |